PETDX

PetDx was a San Diego-based veterinary molecular diagnostics company that developed OncoK9, the first and only liquid biopsy multi-cancer early detection (MCED) test for dogs. Founded in 2019, the company used next-generation sequencing (NGS) to detect cancer-associated genomic alterations from a simple blood draw, enabling veterinarians to screen asymptomatic dogs for many types of cancer at scale. PetDx partnered with IDEXX Diagnostics and Antech Diagnostics to expand access to OncoK9, and raised $72 million in total funding including a $62 million Series B in 2021. The company ceased operations in March 2024 due to funding constraints, laying off all employees and halting sample processing.